摘要
目的:探讨西洛他唑对糖尿病大鼠肾组织细胞间粘附分子1(ICAM-1)的影响及对肾脏的保护作用。方法:用链脲佐菌素制备糖尿病大鼠模型。正常对照组(10只),糖尿病对照组(15只),高剂量西洛他唑组(11只,25 mg.kg-1.d-1),低剂量西洛他唑组(13只,18 mg.kg-1.d-1),治疗12周。用微量法分别测血糖、糖化血红蛋白及肾重/体重的比值,分别检测肾脏ICAM-1 mRNA及ICAM-1蛋白表达。结果:与正常组相比,糖尿病组血糖、糖化血红蛋白明显升高;与糖尿病组相比,高、低剂量西洛他唑组血糖、糖化血红蛋白水平差异无统计学意义(P>0.05)。糖尿病组肾重/体重比值明显增加,高、低剂量西洛他唑有减轻肾脏肥大趋势,但与糖尿病组的差别无统计学意义(P>0.05);ICAM-1 mRNA表达在糖尿病组明显升高,西洛他唑组有显著改善(P<0.01);免疫荧光染色显示,糖尿病组ICAM-1在肾组织分布广且呈强阳性表达,而西洛他唑组ICAM-1着色弱,分布局限;Western blot检测显示,正常组ICAM-1蛋白表达较弱,糖尿病组显著增强,经西洛他唑治疗的糖尿病大鼠ICAM-1蛋白表达降低。结论:链脲佐菌素诱发的糖尿病大鼠肾脏ICAM-1表达增加,西洛他唑可降低糖尿病大鼠肾组织ICAM-1 mRNA和蛋白表达,可能对糖尿病肾病具有保护作用。
Objective： To investigate the effect of cilostazol on intercellular adhesion molecule-1 （ICAM-1） in kidney of diabetic rats and the protective effect of cilostazol on diabetic kidney. Methods： The diabetic model of male SD rat was prepared by streptozocin （STZ） intraperitoneally. There were 4 groups：normal control group（n=10）, diabetic control group（n=15）, high-dose of cilostazol group（n=15, 25 ·kg^-1·d^-1） and low-dose of eilostazol group （n=15, 18 ·kg^-1·d^-1）. Treatment for 12 weeks, all animals were sacrificed. The fasting blood glucose（BG）, HbAlc, the ratio of kidney weight to body weight were measured; the ICAM-I mRNA level of kindey was semi-quantitated by RT-PCR; the expression of ICAM-1 protein of kidney was detected by western blot; the ICAM-1 location tested by immunofluorescenee. Results： The levels of BG and HbAle in diabetic control group were higher than those in normal control group （P〈0.05）. Compared with diabetic group, the levels of BG and HbAle did not decrease significantly in both eilostazol treatment group, Compared with normal control group, the ratio of kidney weight to body weight significantly increased in diabetic control group （P〈0.01）and Cilostazol treatment groups （P〈0.01）. The expression of renal ICAM-1 mRNA in diabet6ic control group was significant higher than that in other groups,but showed a down- regulation in cilostazol groups（P〈0.01）. By immunofluoeseenee, ICAM-1 staining in diabetic group was strong and located at fargoing kidney tissues, but was weak and located within limits in diabetic animals with cilostazol treatmeat. By western blotting, expression of ICAM-1 protein of kidney was weak in normal control group, increased significantly in diabetic control group, and had a tendency to decrease after the treatment with eilostazol. Conclusion： The expression of ICAM-1 increases in kidney of the STZ-induced SD diabetic rat. Cilostazol can protect the kidney by decreasing the expression of ICAM-1 and delay the development of diabetic nephropathy.
出处
《山东大学学报（医学版）》
CAS
北大核心
2006年第1期54-59,共6页
Journal of Shandong University:Health Sciences
基金
山东省科技厅资助项目(编号:1999BB1DBA4)
关键词
细胞粘附分子
糖尿病
实验性
糖尿病肾病
西洛他唑
Cell adhesion molecules
Diabetes mellitus, experimental
Diabetic nephropathies
Cilostazol
